Background
The invention involves synthesis of a new type of diastereomeric chiral dinuclear platinum complex anticancer drug that has higher tolerability and lower side effects than the current very effective but toxic anticancer platinum drug, oxaliplatin.

To access the rest of the information on this page,
Log In or sign up for a free B-Bridge account: